Drugs / L-alanyl-L-glutamine dipeptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04560309 | Jan → Oct 2021 | coronary artery disorder | National Cardiovascular Center Harapan Kita Hospital Indonesia | Completed | Mixed |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-alanyl-L-glutamine dipeptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04560309 ↗ |
| Modality | Peptide | “L-alanyl-L-glutamine dipeptide” NCT04560309 ↗ |
| Route | Intravenous | “Intravenous infusion of 0.5 mg/kgbw L-alanyl-L-glutamine dipeptide” NCT04560309 ↗ |